Rossari Biotech has approved the grant of 8,30,050 stock options to eligible employees under its Rossari Employee Stock Option Plan – 2019 (ESOP 2019). The Board determined the exercise price at ₹537 per option. Each option will convert into one equity share of the face value ₹2 upon vesting and exercise. The options will vest over four years, with 20% vesting at the end of each of the first three years and the remaining 40% at the end of the fourth year. Vested options can be exercised within five years from the date of vesting.

The Board also recommended the re-appointment of Ms. Esha Padmanabhan Achan as a Non-Executive Independent Director for a second term of three consecutive years. Her tenure is scheduled to commence on October 21, 2026, and conclude on October 20, 2029, subject to the approval of the company's members. Ms. Achan is a finance professional with 33 years of experience, having held senior roles at Glenmark Pharmaceuticals and Bajaj. She holds no shareholding in the company and is not related to any other directors.

The ESOP 2019 is formulated in terms of the Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014. The Nomination and Remuneration Committee administers the plan and determines the eligibility criteria for grants. The exercise price is set by the Board or the committee, ensuring it is not less than the face value of the shares.

Key Details of ESOP Grant

Director Re-appointment Details

Rossari Biotech Limited has announced its Q4 and FY26 earnings results, recording the highest quarterly and annual performance across key financial metrics. The company reported revenue from operations of Rs. 684.9 crore for Q4 FY26, representing an 18% year-on-year growth from Rs. 579.6 crore in Q4 FY25. EBITDA stood at Rs. 77.3 crore with a margin of 11.3%, while profit after tax reached Rs. 46.0 crore, marking a 34% increase compared to the same period last year.

Q4 FY26 Financial Highlights

The company achieved its highest quarterly revenue, EBITDA and PAT during the quarter. All business segments - HPPC, TSC and AHN - delivered healthy double-digit growth during the quarter, reflecting the strength of the diversified portfolio.

FY26 Annual Performance

For the full financial year ended March 31, 2026, Rossari Biotech recorded its highest annual revenue of Rs. 2,396.4 crore, growing 15% from Rs. 2,080.3 crore in FY25. Annual EBITDA increased to Rs. 286.0 crore with a margin of 11.9%, while PAT rose to Rs. 149.2 crore, up 9% from the previous year.

Management Commentary

Commenting on the performance, Mr. Edward Menezes, Promoter & Executive Chairman, and Mr. Sunil Chari, Promoter & Managing Director, stated that the company concluded the year on a strong note with Q4 FY26 marking the highest-ever quarterly revenue and EBITDA performance. They highlighted that the diversified portfolio and balanced presence across end-user industries helped navigate a mixed operating environment, including volatility from ongoing geopolitical conflicts.

The management noted that margins during the quarter were impacted by the prevailing raw material situation and lag in passing on cost inflation. They remain focused on calibrated pricing actions, improving product mix and driving operating leverage to support margin recovery over time.

Key Developments

Unitop commissioned the remaining 15,000 MTPA ethoxylation capacity at its Dahej facility on March 31, 2026, taking total installed ethoxylation capacity to 66,000 MTPA. The Board of Directors recommended a dividend of Re. 0.50 per share for FY 2025-26.

The company established a new Research and Development Facility at Koparkhairane, Navi Mumbai, and shifted its existing R&D facility from IIT Bombay. This transition marks a significant step-up in scale and ambition, positioning the company to drive faster innovation cycles and strengthen its competitive moat. Mr. Udeypaul Singh Gill was appointed as an Additional Director designated as Non-Executive, Independent Director of the company.

Regulatory Compliance

Pursuant to Regulation 30 and 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company published an extract of its consolidated audited financial results for the quarter and financial year ended March 31, 2026 in Financial Express (English) and Loksatta (Marathi) newspapers on April 28, 2026.